Skip to main content

Table 2 BMD data at baseline, 6- and 12-months. Comparison of BMD at baseline and its changes at 6- and 12-months in patients with established osteoporosis compared between Alendronate group and placebo control group (Data: mean ± SD)

From: Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis

BMD measurements Placebo control group (n = 25) Alendronate group (n = 22)
   Baseline 6-month 12-month % difference + Baseline 6-month 12-month % difference +
DXA (g/cm2) Spine (L2-L4) 0.718 ± 0.101 0.709 ± 0.105 0.710 ± 0.102 -0.7 ± 3.3 0.719 ± 0.097 0.743 ± 0.101 * 0.756 ± 0.094 ** 5.1 ± 4.2 a
  Femoral Neck 0.631 ± 0.060 0.633 ± 0.053 0.632 ± 0.055 -0.1 ± 4.1 0.653 ± 0.121 0.658 ± 0.129 0.670 ± 0.129 ** 2.5 ± 3.2 b
pQCT (mg/cm3) Distal radius tBMD 138.6 ± 29.3 135.3 ± 31.5 137.3 ± 31.9 -0.6 ± 6.4 126.8 ± 46.4 130.4 ± 44.3 * 130.8 ± 44.5 * 0.9 ± 5.1
  iBMD 424.5 ± 73.0 421.0 ± 75.6 429.9 ± 82.3 0.1 ± 3.2 388.1 ± 79.4 383.4 ± 79.6 385.4 ± 91.0 0.2 ± 3.8
  cBMD 1124.2 ± 172.9 1070.7 ± 289.3 1113.0 ± 178.4 ** -1.4 ± 2.2 1084.3 ± 202.8 1024.7 ± 329.8 1077.6 ± 203.3 0.1 ± 2.4 b
  1. +: percentage compared between baseline and 12-month
  2. * p < 0.05; **p < 0.01: compared with baseline
  3. a: p < 0.01; b: p < 0.05: compared for changes in BMD between Alendronate and placebo control group